Dr. Sam Fang

Dr. Fang brings three decades of global leadership, entrepreneurial, and professional experience with broad business development, operational, regulatory, and trans-continent actional expertise in the pharmaceutical sector to his current role as Chief Active Pharmaceutical Ingredient Officer at PharmaRen. He is also a founding executive member and CEO of ACANA PHARMATECH, a company based in Shanghai. At ACANA, he led cGMP manufacturing of the complex anticoagulant Fondaparinux. He oversaw and administered compliance, IP, security, privacy, public affairs, and government affairs of the company. He was the key player in bringing the Generic injectable Fondaparinux to the US market from the R&D stage through fill-finish and packaging. His cooperation with PharmaRen started in 2014. He has been a shareholder, partner, and key member of the PharmaRen scientific team in leading the scale-up development efforts. His team has prepared a complete technical package for the production of Epothilone B under cGMP guidelines.